A “Future Directions” report appearing in this month’s issue of Inflammatory Bowel Diseases characterizes the specialty medical home as a promising new approach to the delivery of patient centered, cost effective care for patients with Crohn’s disease and ulcerative colitis. Author Miguel Regueiro, MD, with the University of Pittsburg Medical Center and UPMC Health Plan detail the center’s experience with the development of the inflammatory bowel diseases specialty medical home (IBD SMH) describing it as “a new model of care that places the patient at the center of the medical universe.” Beyond optimizing medical and surgical care the IBD SMH approach seeks to enhance behavioral skills, improve social support, and reduce stress, anxiety, and depression that frequently accompanies these chronic, painful medical conditions.
A news summary about the specialty medical home approach, with link to the journal article, may be read here.
In a separate development on the therapy front for IBD, researchers from University of California San Diego School of Medicine report results of a Phase II clinical trial demonstrating that a novel drug molecule, ozanimod (RPC1063), is moderately effective for treating ulcerative colitis. This debilitating disease is accompanied by an abnormal accumulation of T-cells in the gut lining, whose activation causes inflammation and chronic, painful diarrhea. The research found that ozanimod, manufactured by Receptos, Inc., halted the recruiting of cells for an immune response. Lead author William J. Sandborn, MD, commented, “Unlike other currently available drugs for inflammatory bowel disease, ozanimod can be orally administered and does not suppress the immune system to the point of increasing likelihood of infection or cancer.” The findings appear in the May 5 issue of New England Journal of Medicine.
To access the painweek.org library of information about IBD, tap here.
More about the new treatment approach may be read here.
The journal abstract may be read here.